Postpartum Severe Preeclampsia Maternal Outcomes In 12-Hours Versus 24-Hours Maintenance Doses of Magnesium Sulfate Administration: Randomized Control Trial

Phase 2

Completed

• Conditions: Severe preeclampsia; Preeclampsia

• Registration Number: TCTR20230811008
• Lead Sponsor: ocal, in Arifin Achmad Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2023-01-10
• Study Start: 2023-08-11
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 80

Inclusion Criteria

All pregnant women diagnosed with severe preeclampsia who are eligible for magnesium sulfate administration get a loading dose of magnesium sulfate Zuspan. Postpartum severe preeclampsia mothers who received a maintenance dose of magnesium sulfate Zuspan.

Exclusion Criteria

All severe preeclampsia patients with decreased consciousness; had complications such as eclampsia, HELLP syndrome, kidney failure, or acute pulmonary edema; were in labor; received antihypertensive therapy in the last 12 hours; had an allergy to the trial drugs; and had asthma and heart disease were excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Maternal Outcome 42 days Direct assessment

Secondary Outcome Measures

Name	Time	Method
Side Effects and Clinical Symptoms of MgSO4 Toxicity 24 hours Interview and Direct assessment